HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Up 151.7% in January

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 53,964 shares, an increase of 151.7% from the January 15th total of 21,438 shares. Based on an average daily volume of 93,084 shares, the short-interest ratio is presently 0.6 days. Currently, 2.9% of the company’s shares are sold short. Currently, 2.9% of the company’s shares are sold short. Based on an average daily volume of 93,084 shares, the short-interest ratio is presently 0.6 days.

HCW Biologics Trading Down 21.2%

Shares of NASDAQ HCWB traded down $0.18 during midday trading on Friday, hitting $0.65. The company’s stock had a trading volume of 617,486 shares, compared to its average volume of 77,545. The business’s 50 day moving average is $1.32 and its two-hundred day moving average is $2.94. HCW Biologics has a 12-month low of $0.65 and a 12-month high of $17.80. The firm has a market cap of $2.13 million, a P/E ratio of -0.05 and a beta of 0.72.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings data on Friday, November 14th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of $1.58 by ($3.60). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $7.00 million.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC bought a new position in HCW Biologics Inc. (NASDAQ:HCWB) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned approximately 0.69% of HCW Biologics at the end of the most recent reporting period. 2.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.00.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.